<DOC>
	<DOCNO>NCT00482755</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving sunitinib surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well sunitinib work treat patient newly diagnose stage II stage IIIA breast cancer remove surgery .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Newly Diagnosed Stage II Stage III Breast Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility neoadjuvant sunitinib malate patient newly diagnose , resectable stage II-IIIA breast cancer . Secondary - Determine nature , severity , frequency adverse event patient treated drug . - Determine response rate patient treat drug . - Evaluate marker angiogenesis ( e.g. , VEGF receptor , platelet-derived growth factor receptor , circulate plasma VEGF , sVEGFR-2 , sVEGFR-3 , sKIT , tumor vascularity ) pre- post-treatment . - Examine role host- tumor-specific gene pertain response toxicity . - Compare tumor vascular parameter pre- post-treatment use DCE-MRI . - Compare cell death tumor microcirculation pre- post-treatment use contrast-enhanced spectroscopic microbubble contrast-enhanced ultrasound . - Compare tumor metabolic activity pre- post-treatment use fludeoxyglucose F 18-PET . OUTLINE : This multicenter study . Patients receive oral sunitinib malate daily 14-21 day absence disease progression unacceptable toxicity . Tissue sample obtain needle biopsy baseline day 14-21 . Blood sample collect baseline , day 14-21 , 4 week post-treatment pharmacodynamic study . Markers angiogenesis ( VEGF receptor , platelet-derived growth factor receptor , VEGF , sKIT , tumor vascularity ) detect immunohistochemistry . DCE-MRI fludeoxyglucose F 18-PET conduct research study baseline day 14-21 . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Newly diagnose disease Stage IIIIIA ( T1c , T2 , T3 ) disease Unifocal disease Resectable disease Tumor must suitable multiple biopsy image No prior breast cancer Hormone receptor status specify PATIENT CHARACTERISTICS : Male female Menopausal status specify ECOG performance status 01 Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine normal Calcium ≤ 3 mmol/L Bilirubin normal ALT AST ≤ 2.5 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy except adequately treat nonmelanoma skin cancer , curatively treated situ cancer cervix , solid tumor curatively treat evidence disease ≥ 5 year No QTc prolongation ( define QTc interval ≥ 500 msec ) significant ECG abnormalities No history serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No prior concurrent NYHA class IIIV cardiovascular disease No inadequately control hypertension ( systolic BP ≥ 140 mm Hg diastolic BP ≥ 90 mm Hg ) No myocardial infarction , cardiac arrhythmia , stable unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within past 12 month No pulmonary embolism within past 12 month No cerebrovascular accident transient ischemic attack within past 12 month No serious illness medical condition would preclude study compliance include , limited , follow : History significant neurologic psychiatric disorder Active uncontrolled infection Serious nonhealing wound , ulcer , bone fracture No medical condition could interfere oral medication intake ( e.g. , frequent vomiting , malabsorption ) No history allergic reaction attribute compound similar chemical composition sunitinib malate No preexisting hypothyroidism unless patient euthyroid medication PRIOR CONCURRENT THERAPY : At least 7 day since prior concurrent CYP3A4 inhibitor , include follow : Azole antifungal ( ketoconazole , miconazole ) Verapamil Clarithromycin HIV protease inhibitor ( indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) Erythromycin Delavirdine Diltiazem At least 12 day since prior concurrent CYP3A4 inducer , include follow : Rifampin Phenytoin Rifabutin Hypericum perforatum ( St. John 's wort ) Carbamazepine Efavirenz Pentobarbital Tipranavir Phenobarbital No prior protein tyrosine kinase inhibitor No prior antiangiogenic agent No prior hormonal therapy , radiotherapy , chemotherapy , surgery , investigational therapy , therapy breast cancer At least 12 day since prior concurrent cyclooxygenase2 inhibitor ( e.g. , etoricoxib , valdecoxib , celecoxib , dual cyclooxygenase/lipid oxidation , lumiracoxib ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent agent proarrhythmic potential ( e.g. , terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide , flecainide ) No concurrent treatment breast cancer No concurrent coumadinderivative anticoagulant ( e.g. , warfarin ) Anticoagulants ≤ 2 mg/day prophylaxis thrombosis allow Low molecular weight heparin allow provide INR ≤ 1.5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>male breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>